- Home
- LAMR vs VTRS Comparison
LAMR vs VTRS Comparison
Compare LAMR & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAMR
- VTRS
- Stock Information
- Founded
- LAMR 1902
- VTRS 1961
- Country
- LAMR United States
- VTRS United States
- Employees
- LAMR N/A
- VTRS N/A
- Industry
- LAMR Real Estate Investment Trusts
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- LAMR Real Estate
- VTRS Health Care
- Exchange
- LAMR Nasdaq
- VTRS Nasdaq
- Market Cap
- LAMR N/A
- VTRS 12.9B
- IPO Year
- LAMR 1996
- VTRS N/A
- Fundamental
- Price
- LAMR $135.96
- VTRS $11.71
- Analyst Decision
- LAMR Hold
- VTRS Hold
- Analyst Count
- LAMR 5
- VTRS 3
- Target Price
- LAMR $125.00
- VTRS $12.33
- AVG Volume (30 Days)
- LAMR 411.2K
- VTRS 8.9M
- Earning Date
- LAMR 11-08-2024
- VTRS 11-07-2024
- Dividend Yield
- LAMR 4.11%
- VTRS 4.11%
- EPS Growth
- LAMR 20.20
- VTRS N/A
- EPS
- LAMR 4.93
- VTRS N/A
- Revenue
- LAMR $2,164,433,000.00
- VTRS $15,239,200,000.00
- Revenue This Year
- LAMR N/A
- VTRS N/A
- Revenue Next Year
- LAMR $4.87
- VTRS N/A
- P/E Ratio
- LAMR $27.72
- VTRS N/A
- Revenue Growth
- LAMR 4.10
- VTRS N/A
- 52 Week Low
- LAMR $79.94
- VTRS $8.74
- 52 Week High
- LAMR $139.88
- VTRS $13.62
- Technical
- Relative Strength Index (RSI)
- LAMR 62.96
- VTRS 54.75
- Support Level
- LAMR $130.39
- VTRS $11.28
- Resistance Level
- LAMR $139.88
- VTRS $11.93
- Average True Range (ATR)
- LAMR 2.05
- VTRS 0.21
- MACD
- LAMR 0.06
- VTRS 0.04
- Stochastic Oscillator
- LAMR 60.28
- VTRS 68.12
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.